Stereotaxis this week announced it has forged a broad collaboration with Shanghai Microport EP Medtech to advance technology innovation and commercial adoption of electrophysiology robotics in China.
The agreement combines MicroPort EP’s commercial and product expertise in China’s electrophysiology market and Sterotaxis’s Robotic Magnetic Navigation technology. Through the collaboration, MicroPort EP will be the exclusive distributor of StereoTaxis’s Robotic Magnetic Navigation system for electrophysiology in China. MicroPort will also pursue regulatory approvals for Stereotaxis’s innovations including the Genesis RMN system and other magnetic ablation catheters.
Stereotaxis’s robotic systems will also be integrated with MicroPort EP’s Columbus mapping system through the agreement. Both companies will work to develop a family of cardiac ablation and diagnostic catheters.
“I am very excited by the promise of this collaboration,” Jin Qi, a doctor at Ruijin Hospital in Shanghai said in a news release. “Having completed nearly 2,000 robotic ablations, I deeply understand the value of robotic technology and appreciate how this partnership will expand broad access to these benefits for hospitals, physicians and their patients across China.”
The term of the agreement will extend through 2028.
“Stereotaxis and MicroPort EP are delighted to enter into this strategic collaboration and are confident it will benefit both companies along with the electrophysiologists and arrhythmia patients we serve,” said David Fischel, CEO of Stereotaxis and Sun Yiyong, president of MicroPort EP. “We look forward to providing China’s electrophysiology community with highly innovative and differentiated products that leverage Robotic Magnetic Navigation technology. This will both strengthen the importance of robotics and reinforce the key role of MicroPort EP in this rapidly growing and underserved market.”